Drug Trial Radar · NCT02614794
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
Last checked: Nov 20, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
612
Actual
Start
Jan 28, 2016
Primary completion
Sep 4, 2019
Study completion Aug 11, 2022
Sponsor
- Lead sponsor
- Seagen Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 25, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. All patients in the study will get capecitabine and trastuzumab, two drugs that are often used to treat this cancer. There are two parts to this study. The first part of the study is already complete. Patients were randomly assigned to get either tucatinib or placebo (a pill with no medicine). Since this part was "blinded," neither patients nor their doctors knew whether a patient got tucatinib or placebo. The second part of the study is called the Unblinded Phase. In this part of the study, participants and their doctors know which drugs are being given. Participants who used to get or are currently getting placebo may be able to start taking tucatinib instead. Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills two times every day. They will swallow capecitabine pills two times a day during the first two weeks of each cycle. Patients will get trastuzumab injections from the study site staff on the first day of every cycle.
Conditions
- HER2 Positive Breast Cancer
Interventions
tucatinibDrug
300 mg orally twice daily
capecitabineDrug
1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
trastuzumabDrug
8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
placeboDrug
Oral dose twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)Time frame: 34.6 months
Locations
176 sites in 15 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of South Alabama - Mitchell Cancer Institute
Mobile, Alabama
Cancer Treatment Centers of America - Phoenix
Goodyear, Arizona
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona
City of Hope National Medical Center
Duarte, California
TRIO - Central Regulatory Office
Los Angeles, California
UCLA Medical Center / David Geffen School of Medicine
Los Angeles, California
Torrance Memorial Physician Network - TRIO
Redondo Beach, California
University of California at San Francisco
San Francisco, California
Kaiser Permanente San Marcos Medical Offices
San Marcos, California
Central Coast Medical Oncology Corporation TRIO
Santa Maria, California
Kaiser Permanente Medical Center Northern California
Vallejo, California
University of Colorado Hospital / University of Colorado
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
Lombardi Cancer Center / Georgetown University Medical Center
Washington D.C., District of Columbia
Florida Cancer Specialists - South Region
Fort Myers, Florida
Memorial Regional Hospital TRIO
Hollywood, Florida
Baptist MD Anderson Cancer Center
Jacksonville, Florida
University of Miami
Miami, Florida
Mount Sinai Medical Center / Florida
Miami Beach, Florida
Orlando Health, Inc. TRIO
Orlando, Florida
Florida Cancer Specialists - North Region
St. Petersburg, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Florida Cancer Specialists - East West Palm Beach, FL (SCRI)
West Palm Beach, Florida
Winship Cancer Institute / Emory University School of Medicine
Atlanta, Georgia
Northside Hospital
Atlanta, Georgia
Augusta University
Augusta, Georgia
Cancer Treatment Centers of America
Newnan, Georgia
Rush University Medical Center
Chicago, Illinois
University of Chicago
Chicago, Illinois
Illinois Cancer Specialists / Advocate Lutheran General Hospital
Niles, Illinois
Carle Cancer Center
Urbana, Illinois
University of Kansas Cancer Center
Westwood, Kansas
University of Maryland
Baltimore, Maryland
Maryland Oncology Hematology, P.A.
Rockville, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
William Beaumont Hospital
Royal Oak, Michigan
Virginia Piper Cancer Institute
Minneapolis, Minnesota
Saint Luke's Cancer Institute LLC
Kansas City, Missouri
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.